CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)
暂无分享,去创建一个
J. Sterne | P. Reiss | T. Sterling | M. Saag | M. Cavassini | F. Dabis | D. Costagliola | M. May | A. Justice | A. Trickey | J. Guest | A. Monforte | C. Stephan | A. van Sighem | P. Schommers | G. Chêne | A. Boulle | H. Crane | L. Shepherd | J. Vehreschild | J. Gill | Colette Smith | J. Miró | N. Obel | V. Lima | R. Zangerle | J. Del Amo | R. Teira | Suzanne M Ingle | D. Haerry | L. Wittkop | M. Cavassini | M. Gill | Matthew Williams | Margaret Johnson | R. Hogg | Jan Tate | Andrew Christoph Jose M Matthias Geneviève Dominique Fran Boulle Stephan Miro Cavassini Chêne Costag | Dominique Costagliola | Dominique Costagliola | D. Costagliola
[1] G. Carcelain,et al. Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first‐line combination antiretroviral therapy , 2015, HIV medicine.
[2] H. Ullum,et al. Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals. , 2015, The Journal of infectious diseases.
[3] A. d’Arminio Monforte,et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. , 2015, The lancet. HIV.
[4] J. Routy,et al. CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients , 2015, Journal of the International AIDS Society.
[5] N. Sachdeva,et al. Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida. , 2014, Immunobiology.
[6] J. Sterne,et al. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). , 2014, International journal of epidemiology.
[7] M. Lederman,et al. HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality , 2014, PLoS pathogens.
[8] J. Sterne,et al. Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] F. Segura,et al. Overall and cause-specific mortality in HIV-positive subjects compared to the general population , 2014, Journal of the International AIDS Society.
[10] P. Sax,et al. Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 , 2014, Journal of acquired immune deficiency syndromes.
[11] A. Royuela,et al. Increased Risk of Serious Non-AIDS-Related Events in HIV-Infected Subjects on Antiretroviral Therapy Associated with a Low CD4/CD8 Ratio , 2014, PloS one.
[12] S. Moreno,et al. The CD4:CD8 ratio is associated with markers of age‐associated disease in virally suppressed HIV‐infected patients with immunological recovery , 2014, HIV medicine.
[13] R. Hogg,et al. Predictors of CD4:CD8 Ratio Normalization and Its Effect on Health Outcomes in the Era of Combination Antiretroviral Therapy , 2013, PloS one.
[14] L. Pirofski,et al. CD8+ T cells and Risk for Bacterial Pneumonia and All-Cause Mortality Among HIV-Infected Women , 2012, Journal of acquired immune deficiency syndromes.
[15] F. Fregonese,et al. Predictors of 5-Year Mortality in HIV-Infected Adults Starting Highly Active Antiretroviral Therapy in Thailand , 2012, Journal of acquired immune deficiency syndromes.
[16] A. Mocroft,et al. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. , 2012, International journal of epidemiology.
[17] B. Gazzard,et al. CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE , 2012, PLoS medicine.
[18] A. Mocroft,et al. A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study , 2011, HIV clinical trials.
[19] S. Deeks,et al. HIV infection, inflammation, immunosenescence, and aging. , 2011, Annual review of medicine.
[20] Ross J. Harris,et al. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] P. Morlat,et al. Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The “Mortalité 2000 and 2005” Surveys (ANRS EN19 and Mortavic) , 2008, Journal of acquired immune deficiency syndromes.
[22] G. Carcelain,et al. CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3 , 2008, Antiviral therapy.
[23] J. Ouslander,et al. T cell subset-specific susceptibility to aging. , 2008, Clinical immunology.
[24] T. Sterling,et al. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. , 2007, The Journal of infectious diseases.
[25] S. Khuder,et al. Predicting AIDS-related events using CD4 percentage or CD4 absolute counts , 2006, AIDS research and therapy.
[26] J. Sterne,et al. Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. , 2005, Journal of clinical epidemiology.
[27] T. Sterling,et al. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. , 2005, The Journal of infectious diseases.
[28] R. Salamon,et al. Determinants of clinical progression in antiretroviral‐naïve HIV‐infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996–2002 , 2005, HIV medicine.
[29] Richard D Moore,et al. Absolute CD4 Vs. CD4 Percentage for Predicting the Risk of Opportunistic Illness in HIV Infection , 2004, Journal of acquired immune deficiency syndromes.
[30] Sunil J Rao,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .
[31] S. Frøland,et al. CD4+ and CD8+ lymphocytes and HIV RNA in HIV infection: high baseline counts and in particular rapid decrease of CD8+ lymphocytes predict AIDS. , 1999, AIDS.
[32] N. Dubin,et al. CD4% is the best predictor of development of AIDS in a cohort of HIV‐infected homosexual men , 1991, AIDS.
[33] U. Dianzani,et al. Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype. , 1994, Blood.
[34] J M Taylor,et al. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. , 1989, Journal of acquired immune deficiency syndromes.